{'fraction_non_alphanumeric': 0.023255813953488372, 'fraction_numerical': 0.0031007751937984496, 'mean_word_length': 5.211538461538462, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Use of plasma‐derived factor X concentrate in neonates and infants with congenital factor X deficiency

Congenital factor X deficiency (FXD) is a rare bleeding disorder that often presents with severe bleeding in the neonatal period. Long‐term prophylaxis with infusions of FX‐containing products is recommended in patients with FXD and a personal or family history of severe bleeding. A plasma‐derived FX concentrate (pdFX) is approved for on‐demand and prophylactic therapy in adults and children with FXD. The safety and efficacy of pdFX has been demonstrated in patients <12 years of age, yet limited data exist regarding its use in infants.